PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Oliveras, L.* ; Coloma, A.* ; Lloberas, N.* ; Lino, L.* ; Fava, A.* ; Manonelles, A.* ; Codina, S.* ; Couceiro, C.* ; Melilli, E.* ; Sharif, A.* ; Hecking, M.* ; Guthoff, M. ; Cruzado, J.M.* ; Pascual, J.* ; Montero, N.*

Immunosuppressive drug combinations after kidney transplantation and post-transplant diabetes: A systematic review and meta-analysis.

Transplant. Rev. 38:100856 (2024)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Post-transplant diabetes mellitus (PTDM) is a frequent complication after kidney transplantation (KT). This systematic review investigated the effect of different immunosuppressive regimens on the risk of PTDM. We performed a systematic literature search in MEDLINE and CENTRAL for randomized controlled trials (RCTs) that included KT recipients with any immunosuppression and reported PTDM outcomes up to 1 October 2023. The analysis included 125 RCTs. We found no differences in PTDM risk within induction therapies. In de novo KT, there was an increased risk of developing PTDM with tacrolimus versus cyclosporin (RR 1.71, 95%CI [1.38-2.11]). No differences were observed between tacrolimus+mammalian target of rapamycin inhibitor (mTORi) and tacrolimus+MMF/MPA, but there was a tendency towards a higher risk of PTDM in the cyclosporin+mTORi group (RR 1.42, 95%CI [0.99-2.04]). Conversion from cyclosporin to an mTORi increased PTDM risk (RR 1.89, 95%CI [1.18-3.03]). De novo belatacept compared with a calcineurin inhibitor resulted in 50% lower risk of PTDM (RR 0.50, 95%CI [0.32-0.79]). Steroid avoidance resulted in 31% lower PTDM risk (RR 0.69, 95%CI [0.57-0.83]), whereas steroid withdrawal resulted in no differences. Immunosuppression should be decided on an individual basis, carefully weighing the risk of future PTDM and rejection.
Impact Factor
Scopus SNIP
Altmetric
3.600
1.526
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Immunosuppression ; Kidney Transplant ; Meta-analysis ; Post-transplant Diabetes; Trial Comparing Tacrolimus; Chronic Allograft Nephropathy; Prospective Randomized-trial; Early Steroid Withdrawal; Plus Mycophenolate-mofetil; Calcineurin-inhibitor; Long-term; Renal-transplantation; Phase-iii; Early Conversion
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 0955-470X
e-ISSN 1557-9816
Zeitschrift Transplantation Reviews
Quellenangaben Band: 38, Heft: 3, Seiten: , Artikelnummer: 100856 Supplement: ,
Verlag Elsevier
Verlagsort Ste 800, 230 Park Ave, New York, Ny 10169 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes Research and Metabolic Diseases (IDM)
POF Topic(s) 90000 - German Center for Diabetes Research
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502400-001
Förderungen Mecanismo para la Recuperacion y la Resiliencia (MRR)
Spanish Government Instituto de Salud Carlos III (ISCIII)
DOI 10.1016/j.trre.2024.100856
WOS ID 001239767800001
Scopus ID 85192183196
PubMed ID 38723582
Erfassungsdatum 2024-06-12
[➜Korrektur melden]